These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38073115)

  • 1. Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors.
    Kapagan T; Bulut N; Erdem GU
    J Oncol Pharm Pract; 2023 Dec; ():10781552231218959. PubMed ID: 38073115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
    Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
    Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
    Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
    Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
    Kapagan T; Bulut N; Demirer S; Erdem GU
    J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
    Hong K; Yao L; Sheng X; Ye D; Guo Y
    Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
    Yildirim HC; Kapar C; Koksal B; Seyyar M; Sanci PC; Guliyev M; Perkin P; Buyukkor M; Yaslikaya S; Majidova N; Keskinkilic M; Ozaskin D; Avci T; Gunes TK; Arcagok M; Topal A; Keskin GSY; Kavgaci G; Yildirim N; Celayir OM; Avci N; Aslan F; Alkan A; Erciyestepe M; Cengiz M; Pehlivan M; Gulmez A; Beypinar I; Basoglu Tuylu T; Kayikcioglu E; Chalabiyev E; Turhal S; Guzel HG; Ayas E; Sahbazlar M; Dulgar O; Demir H; Yavuzsen T; Bayoglu V; Kivrak Salim D; Ozturk B; Ozdemir F; Kara O; Oksuzoglu B; Bal O; Demirci NS; Yilmaz M; Cabuk D; Aksoy S
    J Chemother; 2024 Mar; ():1-7. PubMed ID: 38497444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
    Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
    Trials; 2023 May; 24(1):338. PubMed ID: 37198674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
    Banys-Paluchowski M; Krawczyk N; Paluchowski P
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):56-66. PubMed ID: 30520756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis.
    Bas O; Erul E; Guven DC; Aksoy S
    Support Care Cancer; 2022 Nov; 30(11):9071-9078. PubMed ID: 35972646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
    Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
    West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
    Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.